Sangamo Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and a Favorable Safety Profile

Uncategorized

Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering